Eisai, Purdue insomnia candidate meets in second Phase III

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) said lemborexant met the primary and secondary endpoints in the Phase III SUNRISE 2 trial to treat insomnia. The trial is the second Phase III trial of the dual orexin receptor antagonist to report positive data.

In March, the partners said lemborexant met the primary and secondary endpoints vs. both placebo and zolpidem ER in the one-month Phase III SUNRISE 1 trial (see "Eisai, Purdue's Lemborexant Meets in Phase III for Insomnia")...